November 18, 2020
X-Cell Tool And Mold acquisition by SyBridge Technologies has completed.
X-Cell Tool and Mold acquisition expands SyBridge’s tooling capabilities to include highly complex precision tooling solutions necessary for the medical industry. As a part of SyBridge, X-Cell will be able to leverage design, engineering, supply chain and production capabilities to better serve and grow with its customers.
This transaction marks the first acquisition by SyBridge in the medical tooling industry and supplements SyBridge’s leading presence in the mobility end market through its Concours Technologies subsidiary. New York-based private equity firm Crestview Partners established SyBridge Technologies in 2019 and committed $200 million of equity to create a market leader spanning across end markets, geographies, and advanced technological capabilities to provide value-added manufacturing solutions to its customers.
Tony Nardone, CEO of SyBridge said, “X-Cell is a strong beginning to SyBridge building a leading franchise in the medial tooling industry. Through continuing to grow with new and existing customers and targeted acquisitions which will complement X-Cell, we are highly optimistic about our growth prospects within the medical industry.”
“X-Cell is a terrific addition to SyBridge Technologies,” said Ron Novel, CEO of X-Cell. “We are proud to become the anchor for a new medical business unit. Becoming part of SyBridge is a win-win situation for X-Cell and our employees and we look forward to accelerating growth and expanding our ability to service our customers as part of SyBridge.”